News & Articles

Prospective study published in Clinical Cancer Research shows that women >70 who tested Signatera MRD-negative could avoid surgery and remain progression-free

The partnership will pair Personalis’ NeXT tumor profiling with Natera’s Signatera™ for treatment monitoring